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Port-site metastases following robotic radical cystectomy: A systematic review 1 
and management options. 2 
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Abstract 25 
Background: Port-site metastases (PSM) are a rare occurrence in robotic surgery. For robot 26 
assisted radical cystectomy (RARC), isolated cases have been reported but management has not 27 
been described previously. We present a case of PSM that occurred after RARC and perform the 28 
results of our systematic review of previously reported port site metastases, and describe 29 
treatment options. 30 
Methods:  We describe a case of a PSM in a 55-year old gentleman who underwent 31 
intracorporeal RARC. We performed a systematic review of MEDLINE and EMBASE databases 32 
for previously reported PSMs, detailing the stage and grade of the primary tumour, time to 33 
presentation of PSM, treatment offered and outcomes for the identified cases. 34 
Results: We identified four cases of PSMs following RARC in the literature, and included our 35 
case for analysis. All five cases had muscle invasive bladder cancer at time of cystectomy (>T2) 36 
and three of them had local lymph node positive disease. Our aggressive treatment of 37 
chemotherapy, wide surgical excision of PSM and radiotherapy has provided the patient a two-38 
year disease-free status. 39 
Conclusion: PSMs are a rare event in RARC, with only four other cases described in the 40 
literature. Outcomes have are not well reported for all of these cases, and we propose that a 41 
multi-modality treatment consisting of salvage chemotherapy, surgery and radiotherapy should 42 
be considered, but concessions have to be made taking patient factors into account. 43 
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Background: 44 
Port-site metastases (PSM) are a rare complication of minimally invasive surgery. Micali et al., 45 
reported an incidence of 0.09% (10 PSM in 10,912 cases) following a survey of urology 46 
procedures carried out for cancer.
1
 Minimally invasive radical cystectomy is a relatively new 47 
procedure evidenced by inclusion of only 95 cases in the series by Micali et al.
1
 Despite few 48 
large case series, isolated PSMs have been reported.
2
 Urothelial cell carcinoma is chemotherapy 49 
and radiotherapy sensitive
3,4
, and more recent reports that targeting the immune response 50 
improves survival in the advanced and metastatic setting
5
, points to a role for multimodality 51 
therapy in the management of PSM following cystectomy. Herein we describe the incidence of 52 
PSM based on a systematic review and set out management options our experience in relation 53 
to robotic cystectomy. 54 
Case:  55 
A 55-year-old male underwent radical robotic cystoprostatectomy and intracorporeal ileal 56 
conduit formation (iRARC) for poorly differentiated muscle invasive urothelial cell carcinoma. 57 
The resected specimens were removed from the port placed 5 cm above and lateral to the right 58 
and left anterior superior iliac spine in an Endo Catch™ Specimen Pouch (Covidien, Dublin, 59 
Ireland). The tumour was causing high-grade obstruction of the vesicoureteric junction, 60 
resulting in moderate right sided hydronephrosis and a reduced pre-operative eGFR, which 61 
precluded neo-adjuvant chemotherapy. His post-operative recovery was uneventful other than 62 
a suprapubic insertion site wound infection requiring co-amoxiclav (classified as a Clavian Dindo 63 
grade II)
6
. Histopathological assessment confirmed poorly differentiated Grade III urothelial cell 64 
with microscopic extension into perivesical fat. The surgical margin was clear and eighteen 65 
removed nodes were all negative (pT3aN0).  66 
Two months after surgery, the patient developed tenderness over the left lower anterior 67 
abdominal wall. Examination revealed a 7cm x 3 cm mobile mass related to the left iliac fossa 68 
port site. MRI confirmed two discrete, partially enhancing lesions within the abdominal wall 69 
musculature at the left iliac fossa (Image 1). CT imaging excluded other metastatic disease; and 70 
PET CT imaging (Image 2a) confirmed avid tracer uptake establishing a diagnosis of isolated 71 
metastatic disease. A biopsy was not performed and the consensus opinion from a 72 
multidisciplinary team meeting (MDT) was for multimodal therapy based on clinical and 73 
radiological findings. Treatment consisted of 3 cycles of gemcitabine and cisplatin, and interval 74 
imaging showed partial response (Image 2b) after the 3 cycles of chemotherapy had been 75 
administered. The patient was re-discussed at MDT and a planned wide surgical excision of the 76 
PSM and mesh reconstruction was performed 5 weeks after completion of chemotherapy. At 77 
operation, the location of the mass was confirmed within the transverse abdominal and 78 
internal oblique muscles. The mass penetrated to the peritoneal surface with adherence of 79 
sigmoid epiplocica at this point. A partial sigmoid resection was performed to achieve wide 80 
cancer clearance, the left iliac crest limited the distal excision and reconstruction of the 81 
abdominal wall with Strattice™ Reconstructive Tissue Matrix (LifeCell, New Jersey, USA) was 82 
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necessary. Histology confirmed a 40 x 30 mm tumour. The tumour was 4 mm from the iliac 83 
resection margin. Subcutaneous tissue and bundles of striated muscle contained poorly 84 
differentiated urothelial cell carcinoma. Following surgical excision, post-operative external 85 
beam radiotherapy was commenced (week 4) and 45Gy in 25 fractions over 5 weeks with 6MV 86 
photons was delivered using a conformally planned technique.  87 
Surveillance by CT imaging, initially at 3 monthly intervals extending to 6 months after 1 year 88 
was instituted and at 2 years form surgery the patient is recurrence free. 89 
Search criteria and methods: 90 
A literature search was performed using MEDLINE and EMBASE for the following MESH terms: 91 
‘cystectomy’ and ‘robotic’ in the abstract. Articles were excluded if there were no cases of PSM, 92 
duplicate reports, reviews or letters to the editor. Only articles in English were included. 1496 93 
articles matched the search criteria, and 372 duplicates were identified and 30 results were 94 
non-English records. Abstracts and full texts of the remaining 1094 articles were manually 95 
reviewed for reports of PSM occurring post-robotic cystectomy. 96 
 97 
Results: 98 
Four cases describing the occurrence of PSM were identified in patients who underwent RARC 99 
for bladder cancer.
 2,7,8,9
 Three of the cases were reported as part of the International Robotic 100 
Cystectomy Consortium (IRCC) database which collects data from 37 global institutions and 101 
holds 1,586 consecutive cases.
9
 A fourth case was reported by El-Tabey et al., in a series of 17 102 
cases and, we report one occurrence of PSM in our experience of 173 cases as of March 2016. 103 
From these figures, the incidence of PSM following robotic cystectomy for bladder cancer is 104 
currently estimated at between 0.2-0.3%. 105 
Consistent with the case described, all PSM have been associated with muscle-invasive disease, 106 
locally advanced and, or lymph node positive disease. The time to recurrence varies between 2 107 
and 10 months from RARC.
7
 An aggressive multimodal management was pursued for the case 108 
which we describe following a similar planned approach described by El-Tabey.
7
 There is no 109 
information about treatment offered in relation to the remaining cases. This data is 110 
summarised in Table 1, along with the case described in this report.  111 
 112 
Discussion: 113 
The incidence of PSM following RARC of less than 0.5% is greater than for combined 114 
genitourinary cancers (0.09%), laparoscopic prostate cancer surgery (0.1%)
10
 and laparoscopic 115 
radical nephrectomy 0.1%.
1
 The incidence of PSM following cystectomy is lower than for 116 
robotic gynaecological procedures for various cancers (endometrial, cervical, ovarian, fallopian 117 
tube) at between 1.1 and 1.9%.
11,12
 Given the relatively low number of case series reported, the 118 
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incidence for PSM following cystectomy can be considered an estimate and may alter in time. 119 
The incidence of incision site metastases after open radical cystectomy is not well described 120 
and may be under-reported. In a series of 100 consecutive open radical cystectomy cases, we 121 
reported a single case of umbilical site recurrence.
13
 122 
The presumed mechanism for the development of PSM is tumour implantation caused by 123 
cancer cell contamination and the reports of cystectomy PSM occurring in advanced stage and 124 
poorly differentiated disease is consistent with tumour spillage. Contributing plausible factors 125 
are seeding during extraction of the tumor, contact with contaminated laparoscopic 126 
instruments, and the effects of pneumoperitoneal desufflation.
14–16
 Although it is postulated 127 
that PSM can be a result of haematogenic or lymphogenic spread, studies in animal models 128 
have failed to support this; in colorectal cancer haematogenic spread to the liver and lungs 129 
precedes other sites.
17
 In bladder cancer, PSMs have been described as an initial or isolated 130 
event supporting tumour implantation as the main causal factor. 131 
In the absence of guidelines and reported outcomes following treatment, after exclusion of 132 
other local or metastatic disease, we pursued an aggressive multimodal therapy plan and we 133 
acknowledge that decision to treat must be made on a case-by-case basis. As the aetiology of 134 
PSM is likely to be related to mechanical disease dissemination during surgery, aggressive 135 
multi-modal treatment may offer affected patients a tumour-free outcome consistent with the 136 
5 year cancer-free survival for local advanced and node positive disease of between 89% and 137 
29%.
18
 We were unable to find best practice guidance for the management of PSM in other 138 
cancers. A systematic review of PSM in robotic-assisted gynaecological procedures for cancer 139 
outlined the management of 20 cases including combinations of surgical excision, 140 
chemotherapy and radiotherapy, with surgery alone being the commonest (9/20) and 3 141 
patients receiving all three modalities of treatment although long-term cancer specific survival 142 
was not reported.
19
 Benefit from neo-adjuvant chemotherapy in the management of muscle-143 
invasive bladder cancer is well-established and incorporated in current guidelines as is the 144 
benefit in the adjuvant setting.
20–22
 In addition, outcomes for radiotherapy showing a reduction 145 
in local and regional recurrence
23
 have been encouraging and support the multi-modality 146 
approach. Furthermore, recent evidence showing benefit for immunomodulation using 147 
MPDL3280A, an anti-PD-L1 antibody in advanced metastatic bladder cancer may extend the 148 
therapy options.
5
 149 
For the case described herein, the surgical plan considered inserting a spacer after resection of 150 
the port-site metastases to increase the distance between bowel and the radiotherapy target 151 
site minimising toxicity. This was not possible after resecting the tumour mass and sigmoid 152 
colon but remains an option to consider in future cases. A further consideration is the 153 
abdominal wall reconstruction following a wide local excision and in the case described, despite 154 
acellular tissue matrix mesh reconstruction, a hernia developed with necessity for subsequent 155 
reconstruction. 156 
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3660 Da Vinci consoles are currently installed in the world, with 2431 in the United states, 616 157 
in Europe, 441 in Asia and 172 in the rest of the world.
1
 A recent survey by Hu et al. compared 158 
RARC (n = 439) vs ORC (n = 7308) and found that while inpatient costs were similar, higher 30-159 
day and 90-day costs were identified, with higher home health care being utilised.
24
 Bochner et 160 
al compared RARC (n = 60) vs ORC (n = 58) in an randomised control trial  161 
 162 
Conclusion: 163 
The incidence of PSM following robotic radical cystectomy for bladder cancer is low (<0.5%) but 164 
greater than other genitourinary malignancies. PSMs and more likely in the following surgery 165 
for locally advanced and node positive disease and careful attention during extraction is an 166 
important and obvious preventative step. In selected cases, in the absence of other local and 167 
metastatic disease a multimodal treatment strategy involving salvage chemotherapy, surgery 168 
and radiotherapy should be recommended.  169 
 170 
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Figures, tables and images: 174 
 175 
Figure 1: Search strategy and results for literature search 176 
  177 
Total number of studies 
identified through 
database searching, 
n=1496 
Medline, n=510 
Embase, n=986 
Duplicate records, n=372 
Non-English records, n=30 
 
Records screened, 
n=1124 
Studies excluded, n= 0 
Publications with PSM, n=4 
Duplicated reports of PSM, 
n=1 
Full text records, 
n=1094 
Included studies, n=3 
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Case 
No 
Author Tumour 
stage 
&grade 
Time to 
presentation 
Treatment Outcome 
1 El-Tabey 
2005
7
 
T3bN0M
0 G3 
10 months Offered local excision, radiotherapy 
and/or chemotherapy. 
Not stated 
2 Saar, 2014
9
 T>2N1M
0 
- Not stated Not stated 
3 Saar, 2014
9
, 
Raza, 2015
2
 
T>2N1M
0 
3 months Not stated Not stated 
4 Saar, 2014
9
  T>2N1M
0 
- Not stated Not stated 
5 Khetrapal T3N0M0 
G3 
2 months Neoadjuvant chemotherapy, excision, 
adjuvant radiotherapy 
Disease-free at 2 
years 
Table 1: Cancer staging and outcomes for individual cases of port-site metastases. 178 
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 193 
Image 1: CT of the abdomen showing the port-site metastases in the transverse abdominal and internal 194 
oblique muscles. 195 
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 196 
Image 2: CT PET showing PET avid uptake within the abdominal wall musculature pre-chemotherapy (a) 197 
and 3 weeks after 3
rd
 cycle post chemotherapy (b) showing partial response to neo-adjuvant 198 
gemcitabine and cisplatin chemotherapy.   199 
a b 
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